CATX vs. KIDS, BFLY, TMCI, BBNX, NPCE, DCTH, SMLR, TCMD, CLPT, and CVRX
Should you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include OrthoPediatrics (KIDS), Butterfly Network (BFLY), Treace Medical Concepts (TMCI), Beta Bionics (BBNX), NeuroPace (NPCE), Delcath Systems (DCTH), Semler Scientific (SMLR), Tactile Systems Technology (TCMD), ClearPoint Neuro (CLPT), and CVRx (CVRX). These companies are all part of the "medical equipment" industry.
Perspective Therapeutics vs.
OrthoPediatrics (NASDAQ:KIDS) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
OrthoPediatrics received 282 more outperform votes than Perspective Therapeutics when rated by MarketBeat users. However, 97.06% of users gave Perspective Therapeutics an outperform vote while only 64.42% of users gave OrthoPediatrics an outperform vote.
In the previous week, OrthoPediatrics had 6 more articles in the media than Perspective Therapeutics. MarketBeat recorded 9 mentions for OrthoPediatrics and 3 mentions for Perspective Therapeutics. OrthoPediatrics' average media sentiment score of 0.36 beat Perspective Therapeutics' score of 0.31 indicating that OrthoPediatrics is being referred to more favorably in the media.
69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 31.8% of OrthoPediatrics shares are held by company insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
OrthoPediatrics has higher revenue and earnings than Perspective Therapeutics.
OrthoPediatrics presently has a consensus price target of $37.00, suggesting a potential upside of 76.19%. Perspective Therapeutics has a consensus price target of $12.75, suggesting a potential upside of 557.22%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Perspective Therapeutics is more favorable than OrthoPediatrics.
OrthoPediatrics has a net margin of -15.00% compared to Perspective Therapeutics' net margin of -4,096.66%. OrthoPediatrics' return on equity of -5.78% beat Perspective Therapeutics' return on equity.
OrthoPediatrics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Summary
OrthoPediatrics beats Perspective Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Perspective Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Perspective Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:CATX) was last updated on 4/18/2025 by MarketBeat.com Staff
Buy CATX Stock Free CATX Stock Alerts